Li Tang

List of Publications by Year
in descending order

64 papers	5,379 citations	134610 34 h-index	169272 56 g-index
67 all docs	67 docs citations	67 times ranked	10314 citing authors

#	Article	IF	Citations
1	Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nature Immunology, 2021, 22, 746-756.	7.0	160
2	Cytokine engineering for targeted cancer immunotherapy. Current Opinion in Chemical Biology, 2021, 62, 43-52.	2.8	36
3	A Manganese Phosphate Nanocluster Activates the cGASâ€STING Pathway for Enhanced Cancer Immunotherapy. Advanced Therapeutics, 2021, 4, 2100065.	1.6	32
4	Switchable immune modulator for tumor-specific activation of anticancer immunity. Science Advances, 2021, 7, eabg7291.	4.7	24
5	Delivery of STING agonists for adjuvanting subunit vaccines. Advanced Drug Delivery Reviews, 2021, 179, 114020.	6.6	65
6	Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. Nature Biomedical Engineering, 2021, 5, 1411-1425.	11.6	96
7	Synthetic 3D scaffolds for cancer immunotherapy. Current Opinion in Biotechnology, 2020, 65, 1-8.	3.3	6
8	Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nature Immunology, 2020, 21, 1540-1551.	7.0	252
9	Editorial overview: Tissue, cell and pathway engineering: programming biology for smart therapeutics, microbial cell factory and intelligent biomanufacturing. Current Opinion in Biotechnology, 2020, 66, iii-vi.	3.3	0
10	T cell force-responsive delivery of anticancer drugs using mesoporous silica microparticles. Materials Horizons, 2020, 7, 3196-3200.	6.4	12
11	Mechanical Immunoengineering of T cells for Therapeutic Applications. Accounts of Chemical Research, 2020, 53, 2777-2790.	7.6	24
12	Regulatory T cells engineered with TCR signalingâ€"responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Science Translational Medicine, 2020, 12, .	5.8	39
13	Central memory CD8+ TÂcells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. Immunity, 2020, 53, 985-1000.e11.	6.6	107
14	Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine. ACS Central Science, 2020, 6, 404-412.	5.3	45
15	Donor cell engineering with GSK3 inhibitorâ€"loaded nanoparticles enhances engraftment after in utero transplantation. Blood, 2019, 134, 1983-1995.	0.6	13
16	Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. Biomaterials Science, 2019, 7, 1345-1357.	2.6	58
17	Surgery-free injectable macroscale biomaterials for local cancer immunotherapy. Biomaterials Science, 2019, 7, 733-749.	2.6	41
18	A Magnetic Nanovaccine Enhances Cancer Immunotherapy. ACS Central Science, 2019, 5, 747-749.	5.3	8

#	Article	IF	Citations
19	Albumin as a â€œTrojan Horseâ€• for polymeric nanoconjugate transendothelial transport across tumor vasculatures for improved cancer targeting. Biomaterials Science, 2018, 6, 1189-1200.	2.6	19
20	Immunoengineering with biomaterials for enhanced cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1506.	3.3	33
21	Engineering cancer vaccines using stimuli-responsive biomaterials. Nano Research, 2018, 11, 5355-5371.	5.8	29
22	Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nature Biotechnology, 2018, 36, 707-716.	9.4	448
23	Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. Frontiers in Immunology, 2018, 9, 1499.	2.2	119
24	High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry. Nature Communications, 2017, 8, 14069.	5.8	102
25	Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. ACS Nano, 2017, 11, 3089-3100.	7.3	117
26	Selective in vivo metabolic cell-labeling-mediated cancer targeting. Nature Chemical Biology, 2017, 13, 415-424.	3.9	274
27	Abstract B53: T lymphocyte engineering with responsive cytokine nanogels for enhanced efficacy and safety of adoptive cell therapy for cancer. , 2017, , .		0
28	Abstract B59: Enhancing T-cell therapy through TCR signaling-responsive nanogel drug delivery. , 2017, , .		0
29	<i>In Vivo</i> Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics, 2016, 6, 1467-1476.	4.6	34
30	Targeted Delivery of Immunomodulators to Lymph Nodes. Cell Reports, 2016, 15, 1202-1213.	2.9	73
31	Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4601-9.	3.3	71
32	Abstract A073: Carrier-free delivery of cytokine to specifically expand adoptively transferred T cells for enhanced cancer immunotherapy. , 2016, , .		0
33	517. Improving CAR T Cell Efficacy for Solid Tumors By Nanogel-Based Delivery of Immunomodulatory Proteins. Molecular Therapy, 2015, 23, S207.	3.7	0
34	T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy. , 2015, 3, .		1
35	Bioorthogonal oxime ligation mediated in vivo cancer targeting. Chemical Science, 2015, 6, 2182-2186.	3.7	28
36	Targeting Tumor Vasculature with Aptamer-Functionalized Doxorubicinâ€“Polylactide Nanoconjugates for Enhanced Cancer Therapy. ACS Nano, 2015, 9, 5072-5081.	7.3	70

#	Article	IF	Citations
37	Biomaterial Strategies for Immunomodulation. Annual Review of Biomedical Engineering, 2015, 17, 317-349.	5.7	132
38	Investigating the optimal size of anticancer nanomedicine. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15344-15349.	3.3	523
39	Smart chemistry in polymeric nanomedicine. Chemical Society Reviews, 2014, 43, 6982-7012.	18.7	171
40	Abstract 2792: Engineering T lymphocytes with protein nanogels for cancer immunotherapy. Cancer Research, 2014, 74, 2792-2792.	0.4	1
41	Cell Engineering with Glycogen Synthase Kinase-3 Beta Inhibitor-Loaded Synthetic Nanoparticles Enhances Hematopoietic Engraftment of Bone Marrow Mononuclear Cells Following in Utero Transplantation. Blood, 2014, 124, 2414-2414.	0.6	0
42	Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. Journal of Materials Chemistry B, 2013, 1, 5288.	2.9	167
43	Nonporous silica nanoparticles for nanomedicine application. Nano Today, 2013, 8, 290-312.	6.2	416
44	Size-Dependent Tumor Penetration and <i>in Vivo</i> Efficacy of Monodisperse Drugâ€"Silica Nanoconjugates. Molecular Pharmaceutics, 2013, 10, 883-892.	2.3	145
45	Chainâ€Shattering Polymeric Therapeutics with Onâ€Demand Drugâ€Release Capability. Angewandte Chemie - International Edition, 2013, 52, 6435-6439.	7.2	132
46	Redox-Responsive, Core-Cross-Linked Micelles Capable of On-Demand, Concurrent Drug Release and Structure Disassembly. Biomacromolecules, 2013, 14, 3706-3712.	2.6	160
47	Chainâ€Shattering Polymeric Therapeutics with Onâ€Demand Drugâ€Release Capability. Angewandte Chemie, 2013, 125, 6563-6567.	1.6	26
48	Aptamerâ€Functionalized, Ultraâ€Small, Monodisperse Silica Nanoconjugates for Targeted Dualâ€Modal Imaging of Lymph Nodes with Metastatic Tumors. Angewandte Chemie - International Edition, 2012, 51, 12721-12726.	7.2	96
49	Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A. Journal of Transplantation, 2012, 2012, 1-9.	0.3	41
50	Synthesis and Biological Response of Size-Specific, Monodisperse Drugâ€"Silica Nanoconjugates. ACS Nano, 2012, 6, 3954-3966.	7.3	163
51	Development and Application of Anticancer Nanomedicine. Nanostructure Science and Technology, 2012, , 31-46.	0.1	4
52	The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials, 2012, 33, 1162-1169.	5.7	82
53	Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles. Journal of Analytical Oncology, 2012, 1, 1-9.	0.1	7
54	Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16883-16888.	3.3	287

#	Article	IF	Citations
55	Drug-polyester conjugated nanoparticles for cancer drug delivery. , 2011, 2011, 8337-9.		0
56	Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications. Microscopy Research and Technique, 2010, 73, 901-909.	1.2	42
57	Lymphatic Biodistribution of Polylactide Nanoparticles. Molecular Imaging, 2010, 9, 7290.2010.00012.	0.7	22
58	Polylactideâ€cyclosporin A nanoparticles for targeted immunosuppression. FASEB Journal, 2010, 24, 3927-3938.	0.2	78
59	Lymphatic biodistribution of polylactide nanoparticles. Molecular Imaging, 2010, 9, 153-62.	0.7	9
60	Controlled formulation of doxorubicin-polylactide nanoconjugates for cancer drug delivery. , 2009, 2009, 2400-2.		1
61	Nanopolymeric Therapeutics. MRS Bulletin, 2009, 34, 422-431.	1.7	51
62	Hydrothermal growth of large-scale micropatterned arrays of ultralong ZnO nanowires and nanobelts on zinc substrate. Chemical Communications, 2006, , 3551.	2.2	122
63	Thermo-responsive behavior of novel polyitaconates having pyrrolidinonyl moiety. Macromolecular Rapid Communications, 2000, 21, 567-573.	2.0	2
64	Epitaxial Ag templates on Si(001) for bicrystal CoCrTa media. Journal of Applied Physics, 1997, 81, 4370-4372.	1.1	35